The US Food and Drug Administration has granted an emergency use authorization (EUA) for Access Bio, Inc.’s CareStart lateral-flow COVID-19 antigen test, the company announced on 13 October.
The CareStart test is a lateral flow immunochromatographic assay for detecting the antigen to the SARS-CoV-2 virus in nasopharyngeal swab specimens collected from the patient at the point of care...